Literature DB >> 15155534

Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons.

Theodore J Price1, Amol Patwardhan, Armen N Akopian, Kenneth M Hargreaves, Christopher M Flores.   

Abstract

The prototypical aminoalkylindole cannabinoid WIN 55,212-2 (WIN-2) has been shown to produce antihyperalgesia through a peripheral mechanism of action. However, it is not known whether WIN-2 exerts this action directly via cannabinoid receptors located on primary afferents or if other, perhaps indirect or noncannabinoid, mechanisms are involved. To address this question, we have examined the specific actions of WIN-2 on trigeminal ganglion (TG) neurons in vitro by quantifying its ability to modulate the evoked secretion of the proinflammatory neuropeptide CGRP as well as the inflammatory mediator-induced generation of cAMP. WIN-2 evoked CGRP release from TG neurons in vitro (EC(50)=26 microm) in a concentration- and calcium-dependent manner, which was mimicked by the cannabinoid receptor-inactive enantiomer WIN 55,212-3 (WIN-3). Moreover, WIN-2-evoked CGRP release was attenuated by the nonselective cation channel blocker ruthenium red but not by the vanilloid receptor type 1 (TRPV1) antagonist capsazepine, suggesting that, unlike certain endogenous and synthetic cannabinoids, WIN-2 is not a TRPV1 agonist but rather acts at an as yet unidentified cation channel. The inhibitory effects of WIN-2 on TG neurons were also examined. WIN-2 neither inhibited capsaicin-evoked CGRP release nor did it inhibit forskolin-, isoproteranol- or prostaglandin E(2)-stimulated cAMP accumulation. On the other hand, WIN-2 significantly inhibited (EC(50)=1.7 microm) 50 mm K(+)-evoked CGRP release by approximately 70%. WIN-2 inhibition of 50 mm K(+)-evoked CGRP release was not reversed by antagonists of cannabinoid type 1 (CB1) receptor, but was mimicked in magnitude and potency (EC(50)=2.7 microm) by its cannabinoid-inactive enantiomer WIN-3. These findings indicate that WIN-2 exerts both excitatory and inhibitory effects on TG neurons, neither of which appear to be mediated by CB1, CB2 or TRPV1 receptors, but by a novel calcium-dependent mechanism. The ramifications of these results are discussed in relation to our current understanding of cannabinoid/vanilloid interactions with primary sensory neurons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155534      PMCID: PMC1574952          DOI: 10.1038/sj.bjp.0705778

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  61 in total

Review 1.  Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain.

Authors:  Linda R Watkins; Erin D Milligan; Steven F Maier
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

2.  A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.

Authors:  A G Nackley; R L Suplita; A G Hohmann
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

3.  The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat.

Authors:  T J Price; G Helesic; D Parghi; K M Hargreaves; C M Flores
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

4.  Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels.

Authors:  Hiroyuki Watanabe; Joris Vriens; Jean Prenen; Guy Droogmans; Thomas Voets; Bernd Nilius
Journal:  Nature       Date:  2003-07-24       Impact factor: 49.962

5.  Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212.

Authors:  J Ludovic Croxford; Stephen D Miller
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

6.  The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase.

Authors:  Mauro Maccarrone; Marianna Di Rienzo; Natalia Battista; Valeria Gasperi; Pietro Guerrieri; Antonello Rossi; Alessandro Finazzi-Agrò
Journal:  J Biol Chem       Date:  2003-06-18       Impact factor: 5.157

7.  N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia.

Authors:  Constance J Chu; Susan M Huang; Luciano De Petrocellis; Tiziana Bisogno; Scott A Ewing; Jeffrey D Miller; Robert E Zipkin; Nives Daddario; Giovanni Appendino; Vincenzo Di Marzo; J Michael Walker
Journal:  J Biol Chem       Date:  2003-02-04       Impact factor: 5.157

8.  The actions of anandamide on rat superficial medullary dorsal horn neurons in vitro.

Authors:  E A Jennings; C W Vaughan; L A Roberts; M J Christie
Journal:  J Physiol       Date:  2003-01-31       Impact factor: 5.182

9.  Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.

Authors:  Fabrizio Facchinetti; Elda Del Giudice; Sara Furegato; Marzla Passarotto; Alberta Leon
Journal:  Glia       Date:  2003-01-15       Impact factor: 7.452

10.  Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry.

Authors:  D Bridges; A S C Rice; M Egertová; M R Elphick; J Winter; G J Michael
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  21 in total

1.  A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons.

Authors:  Theodore J Price; Amol M Patwardhan; Christopher M Flores; Kenneth M Hargreaves
Journal:  Neuropharmacology       Date:  2005-04-01       Impact factor: 5.250

Review 2.  Cannabinoid control of neurogenic inflammation.

Authors:  Meagan McKenna; Jason J McDougall
Journal:  Br J Pharmacol       Date:  2020-08-13       Impact factor: 8.739

3.  Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.

Authors:  Mayur Patil; Amol Patwardhan; Margaux M Salas; Kenneth M Hargreaves; Armen N Akopian
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

4.  Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons.

Authors:  Nathaniel A Jeske; Amol M Patwardhan; Nikita Gamper; Theodore J Price; Armen N Akopian; Kenneth M Hargreaves
Journal:  J Biol Chem       Date:  2006-09-05       Impact factor: 5.157

Review 5.  Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.

Authors:  Armen N Akopian; Nikita B Ruparel; Nathaniel A Jeske; Amol Patwardhan; Kenneth M Hargreaves
Journal:  Trends Pharmacol Sci       Date:  2008-12-11       Impact factor: 14.819

Review 6.  The pharmacology of the cannabinoid system--a question of efficacy and selectivity.

Authors:  Christopher J Fowler
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

7.  Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice.

Authors:  Carmen Manzanedo; Marta Rodríguez-Arias; Manuel Daza-Losada; Concepción Maldonado; María A Aguilar; José Miñarro
Journal:  Behav Brain Funct       Date:  2010-03-22       Impact factor: 3.759

8.  Permanent suppression of cortical oscillations in mice after adolescent exposure to cannabinoids: receptor mechanisms.

Authors:  Sylvina M Raver; Asaf Keller
Journal:  Neuropharmacology       Date:  2014-07-15       Impact factor: 5.250

Review 9.  Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.

Authors:  Luciano De Petrocellis; Vincenzo Di Marzo
Journal:  J Neuroimmune Pharmacol       Date:  2009-10-22       Impact factor: 4.147

Review 10.  Modulation of neuropathic-pain-related behaviour by the spinal endocannabinoid/endovanilloid system.

Authors:  Katarzyna Starowicz; Barbara Przewlocka
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-12-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.